Merck Sharp + Dohme Corp.

Xavier Fradera

Yongxin Han

Abdelghani Achab

Wensheng Yu

Hua Zhou

Hongjun Zhang

Nunzio Sciammetta

Meredeth Ann McGowan

Derun Li

Kun Liu

Shuwen He

Liangqin Guo

Yongqi Deng

Alexander Pasternak

David L Sloman

Li Xiao

Catherine M White

Dane James Clausen

Joseph A Kozlowski

Qinglin Pu

Jongwon Lim

Joey Lee Methot

Guoqing Li

Ping Chen

Craig R Gibeau

Indu T Bharathan

Brett A Hopkins

Theodore A Martinot

Xianhai Huang

David James Witter

Purakkattle J Biju

Jason David Katz

Shimin Xu

Feng Ye

Rui Zhang

Chaomin Li

Phieng Siliphaivanh

Zhi-Cai Shi

Jianmin Fu

Jing Su

Matthew Christopher

John W Lampe

Erin F DiMauro

David Jonathan Bennett

Kathryn Ann Lipford

Ravi Kurukulasuriya

Andreas Verras

Timothy A Cernak

Sulagna Sanyal

Zachary G Brill

Brandon A Vara

Meredeth A Mcgowan

Jenny Lorena Rico Duque

Abdelghani A Achab

Jonathan D Bennett

Bridget A Becker

Hua Zhao

Lianqin Guo

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R, R, R, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

Spirotricycle RIPK1 inhibitors and methods of uses thereof

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

Purine inhibitors of human phosphatidylinositol 3-kinase delta

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Growing community of inventors

Boston, MA, United States of America

Xavier Fradera